Table 2. Multivariable analysis for overall survival in AML patients from ZIH cohort.
| Variables | HR (95% CI) | P value |
|---|---|---|
| MYH9 expression (High vs.Low) | 1.50 (1.03,2.19) | 0.034 |
| Age | 1.01 (1.00,1.02) | 0.054 |
| Sex (Female vs.Male) | 0.81 (0.56,1.16) | 0.248 |
| WBC1 | 1.003 (1,1.006) | 0.025 |
| Percent blast | 1.00 (0.99,1.01) | 0.529 |
| Karyotype-risk group | ||
| Intermediate vs. favorable | 4.63 (0.64,33.53) | 0.129 |
| Poor vs. favorable | 13.31 (1.69,105.01) | 0.014 |
| Gene mutations | ||
| FLT3ITD | 1.45 (0.92,2.28) | 0.108 |
| NPM1 | 0.86 (0.54,1.37) | 0.534 |
| CEBPADM2 | 0.31 (0.15,0.64) | 0.002 |
| Treatment protocols3 | ||
| HAA vs.DA | 0.90 (0.56,1.44) | 0.656 |
| IA vs.DA | 0.83 (0.54,1.30) | 0.418 |
Abbreviations:
1
WBC,white blood cell;
2
DM: Double-allele.
3
The protocols used for induction therapy in different groups including homoharringtonine/Ara-C/aclarubicin (HAA)-based treatment group, donorubicin/Ara-C (DA)-based treatment group, and idarubicin/Ara-C (IA)-based; CI, confidence intervals; HR, hazard ratio.